About capricor therapeutics - CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
CAPR At a Glance
Capricor Therapeutics, Inc.
10865 Road to the Cure
San Diego, California 92121
| Phone | 1-858-727-1755 | Revenue | 22.27M | |
| Industry | Pharmaceuticals: Major | Net Income | -40,467,186.00 | |
| Sector | Health Technology | Employees | 160 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CAPR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 21.823 |
| Price to Book Ratio | 4.324 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.248 |
| Enterprise Value to Sales | 15.237 |
| Total Debt to Enterprise Value | 0.014 |
CAPR Efficiency
| Revenue/Employee | 139,190.406 |
| Income Per Employee | -252,919.913 |
| Receivables Turnover | 2.148 |
| Total Asset Turnover | 0.194 |
CAPR Liquidity
| Current Ratio | 7.771 |
| Quick Ratio | 7.771 |
| Cash Ratio | 7.206 |
CAPR Profitability
| Gross Margin | 93.60 |
| Operating Margin | -191.127 |
| Pretax Margin | -181.708 |
| Net Margin | -181.708 |
| Return on Assets | -35.309 |
| Return on Equity | -48.157 |
| Return on Total Capital | -26.926 |
| Return on Invested Capital | -45.746 |
CAPR Capital Structure
| Total Debt to Total Equity | 3.319 |
| Total Debt to Total Capital | 3.212 |
| Total Debt to Total Assets | 2.832 |
| Long-Term Debt to Equity | 2.745 |
| Long-Term Debt to Total Capital | 2.657 |